Brain Multi-Omic Subtypes of Neuroticism Reveal Molecular Signatures linked to Alzheimer's Disease
Zammit, A. R.; Lopes, K. d. P.; Batalha, C. M. P. F.; Yu, L.; Poole, V. N.; Tasaki, S.; Kapasi, A.; Wang, Y.; De Jager, P. L.; Menon, V.; Seyfried, N.; Kaddurah-Daouk, R.; Iturria-Medina, Y.; Bennett, D. A.
Show abstract
ImportanceMolecular mechanisms linking neuroticism with Alzheimers disease traits are unknown. ObjectiveTo identify molecular subtypes of neuroticism and examine their association with ADRD traits. DesignThree ongoing cohort studies were used; Religious Orders Study (ROS), Rush Memory and Aging Project (MAP) and Minority Aging Research Study (MARS), that began enrollment in 1994, 1997, and 2004, respectively. SettingOlder priests, nuns, and brothers from across the U.S. (ROS), older adults (MAP) and older African-American adults (MARS) from across the greater Chicago metropolitan area. Participants1,028 decedents with multi-omic data from the dorsolateral prefrontal cortex (DLPFC), the anterior cingulate cortex (AC), and the posterior cingulate gyrus (PCG). Exposure(s)Eight layers of omics (DNA methylation and histone acetylation from DLPFC; RNA seq from AC, DLPFC, and PCG, single-nucleus RNA, TMT proteomics and metabolomics from DLPFC) and Neuroticism using the 12-item version from the NEO Five-Factor Inventory. Main outcome(s) and measure(s)Person-specific multi-omic molecular pseudotime representing molecular progression from low to high phenotypic expression of neuroticism, and three multi-omic brain molecular subtypes of neuroticism which represent distinct omic pathways from no/low neuroticism to high neuroticism that differ by their omic constituents. Participants are exclusively assigned to the subtype which aligns mostly with their multi-omic profile. ResultsThe top drivers of subtype differentiation were transcriptomic alterations across three brain regions (DLPFC, AC, PCG) which extensively and differentially characterized the subtypes. The subtypes were also differentially associated with AD pathology, temporal lobe atrophy, and AD dementia, with subtype N1 showing the strongest associations. Conclusions and RelevanceNeuroticism may be driven by three distinct molecular subtypes, with subtype N1 driving ADRD-related associations, N2 showing some ADRD associations, and N3 being completely independent of these outcomes. Our data provide novel insights into the biology of individual differences in predispositions of neuroticism and its associations with ADRD traits. Key pointsO_ST_ABSQuestionC_ST_ABSWhat are the brain multi-omics molecular signatures linking neuroticism with Alzheimers diseases and related dementias (AD/ADRDs)? FindingsWe identified three distinct brain multi-omic molecular subtypes reflecting different molecular pathways underlying neuroticism. Top omic features of the subtypes were extensively and differentially characterized by transcriptomic alterations across three brain regions - dorsolateral prefrontal cortex, anterior cingulate cortex, and posterior cingulate gyrus. Subtype N1 was strongly associated with AD pathology, AD dementia, and temporal lobe atrophy. MeaningThe association we typically observe between phenotypic neuroticism and ADRD clinical traits might be largely driven by a molecular pathway underlying this trait.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Association of RDoC dimensions with post-mortem brain transcriptional profiles in Alzheimer’s Disease 96%
- Cross-sectional study of plasma phosphorylated Tau 217 in persons without dementia 96%
- Blood metabolites predicting Mild Cognitive Impairment in the Study of Latinos-Investigation of Neurocognitive Aging (HCHS/SOL) 95%
Similar papers in this journal
- Default mode network tau predicts future clinical decline in atypical early Alzheimer’s disease 97%
- Selective vulnerability and resilience to Alzheimer's disease tauopathy as a function of genes and the connectome 97%
- Glucose metabolism reflects local atrophy and tau pathology in symptomatic Alzheimer’s disease 97%
Similar papers in this journal
- Tau-PET and in vivo Braak-staging as a prognostic marker in Alzheimer’s disease 97%
- TREM2 Risk Variants with Alzheimer’s Disease Differ in Rate of Cognitive Decline 97%
- Differential effects of aging, Alzheimer's pathology, and APOE4 on longitudinal functional connectivity and episodic memory in older adults 97%